What Are The Relative Contraindications For Ablative Laser Skin Resurfacing? Key Clinical Conditions To Screen For

The key relative contraindications are conditions that impair wound healing, increase infection or scarring risk, damage skin appendages, or worsen with trauma. These include recent isotretinoin use, keloid or hypertrophic scarring, collagen vascular disease, immunosuppression, prior radiation or deep chemical injury to the treatment area, active or recurrent infection, koebnerizing dermatoses, and poorly controlled systemic disease.

Ablative resurfacing creates a controlled wound, so candidates need reliable healing capacity, stable skin, and adequate systemic control. Conditions such as active infection or uncontrolled illness may require postponement or treatment optimization rather than proceeding as planned.

Conditions That Increase Abnormal Scarring or Delayed Healing

Recent isotretinoin exposure

Recent or ongoing systemic isotretinoin is a concern because it may impair re-epithelialization, wound healing, and collagen remodeling, potentially increasing the risk of hypertrophic scarring.

The appropriate waiting period is not universally fixed. The primary reference identifies the preceding 1–2 years, while other clinical sources commonly use 6–12 months; clinicians should follow current specialty guidance, the drug exposure history, treatment intensity, and individual risk factors.

Keloid or hypertrophic scar history

A personal history of keloids or hypertrophic scars is a major warning sign. Ablative injury can provoke excessive scar formation, particularly in patients with a demonstrated tendency to heal abnormally.

This risk applies regardless of whether the planned procedure uses fractional CO₂, Er:YAG, or another ablative platform.

Immunosuppression

Immunosuppressive therapy and significant immunodeficiency can delay healing and increase susceptibility to bacterial, viral, and fungal infection.

The clinician should clarify the medication, degree of immune suppression, underlying disease, and whether treatment can be safely performed after medical optimization.

Collagen vascular and connective-tissue disease

Active scleroderma, systemic lupus erythematosus, and other collagen vascular diseases may alter inflammation, collagen remodeling, and wound repair.

These conditions are not automatically equivalent in severity, but active or poorly controlled disease warrants specialist assessment before resurfacing.

Conditions That Damage the Skin’s Healing Apparatus

Prior radiation therapy

Prior radiation to the treatment area can damage hair follicles and other epidermal appendages that contribute to re-epithelialization.

Healing may therefore be delayed or incomplete, especially when radiation injury is extensive or combined with other wound-healing risks.

Deep phenol peels or burn scars

A history of deep phenol peeling or significant burn scarring may indicate loss or impairment of adnexal structures.

Because these structures help repopulate the surface after ablation, treatment areas with substantial damage require particularly cautious evaluation.

Infection-Related Risks

Active cutaneous infection

Active bacterial, viral, or fungal infection in or near the treatment area generally requires postponement until the infection has resolved.

Ablation disrupts the epidermal barrier and can worsen infection, delay healing, or facilitate spread.

Herpes simplex history

Active herpes simplex is a reason to defer treatment. A history of recurrent herpes labialis is not necessarily a permanent contraindication, but it creates a predictable reactivation risk.

For full-face or perioral resurfacing, clinicians commonly use prophylactic oral antiviral therapy beginning on or before treatment and continuing through the early healing period, often about 7–10 days, according to the clinician’s protocol.

HIV/AIDS or other major immune compromise

Advanced HIV/AIDS or substantial immune compromise may increase infection and healing risks. HIV infection alone should not be treated as an automatic contraindication; the relevant factors include immune status, viral control, medications, and comorbidities.

Likewise, hepatitis C should be evaluated in clinical context rather than treated as an automatic prohibition in every patient.

Skin Diseases That May Koebnerize

Active vitiligo

Active vitiligo may worsen or develop at sites of trauma through the Koebner phenomenon.

Ablative resurfacing should generally be deferred until the condition is stable, with careful discussion of pigmentary risks.

Unstable psoriasis

Active or unstable psoriasis can produce new lesions in injured skin. This makes aggressive resurfacing inappropriate until the disease is controlled.

Severe eczema and other inflammatory dermatoses

Severe eczema, active dermatitis, lichen planus, and similar inflammatory disorders can impair barrier recovery and increase postoperative inflammation.

The treatment area should be clinically quiet before proceeding.

Systemic Conditions That Make Treatment Unsafe

Significant cardiovascular disease

Unstable or significant cardiovascular disease may increase procedural and anesthetic risk, particularly when extensive resurfacing, sedation, or prolonged wound care is anticipated.

The patient’s cardiovascular status should be stable and appropriately cleared before treatment.

Uncontrolled hypertension

Uncontrolled hypertension can increase bleeding, cardiovascular, and peri-procedural risks.

Blood pressure should be assessed and controlled before elective ablative resurfacing.

Unstable diabetes

Poorly controlled or unstable diabetes can impair immune function and wound healing while increasing infection risk.

Glycemic control, diabetes-related complications, and the planned treatment intensity should be considered together.

Additional Factors That Require Risk Adjustment

Darker skin phototypes

Fitzpatrick IV–VI skin types are not necessarily contraindicated, particularly with modern fractional systems, but they carry a higher risk of post-inflammatory hyperpigmentation and other dyschromias.

Lower fluence, conservative settings, fewer passes, and careful postoperative photoprotection may be appropriate.

Prior lower blepharoplasty

A history of external lower blepharoplasty can increase the risk of lower-eyelid malposition or ectropion when treating the infraorbital region.

This is a procedure-specific anatomical risk rather than a systemic contraindication.

Inability to follow aftercare

Although not a clinical disease, inability or unwillingness to perform wound care, avoid sun exposure, or attend follow-up substantially increases complication risk.

In practice, this may be a reason to defer treatment or choose a less aggressive modality.

Understanding the Trade-offs

Relative does not mean insignificant

A relative contraindication does not always mean “never treat.” It means the risk may be acceptable only after stabilization, modification of the treatment plan, specialist input, or informed consent.

Some risks are functionally absolute

Active infection, uncontrolled systemic disease, and severe inability to comply with wound care often make treatment unsafe at that time, even if they are categorized as relative in a screening framework.

The correct action is usually to postpone and address the underlying problem, not simply proceed with reduced laser settings.

Risk factors can compound each other

A patient with several moderate risks—such as recent isotretinoin exposure, darker skin phototype, diabetes, and a history of hypertrophic scarring—may have a substantially higher overall risk than the individual factors suggest.

Screening should therefore assess the complete risk profile rather than rely on a single yes-or-no contraindication list.

Making the Right Choice for Your Goal

Candidate selection should match the patient’s healing capacity, disease stability, skin characteristics, and ability to complete postoperative care.

If your primary focus is wound healing: Defer treatment for recent isotretinoin exposure, active collagen vascular disease, significant immunosuppression, prior radiation injury, or unstable diabetes until risk is appropriately assessed and controlled.
If your primary focus is preventing infection: Do not treat through active bacterial, viral, or fungal infection, and use an appropriate antiviral prophylaxis strategy for patients at risk of herpes reactivation.
If your primary focus is preventing abnormal scars: Treat a history of keloids or hypertrophic scars as a major contraindication or strong reason to select a nonablative alternative.
If your primary focus is avoiding pigment complications: Use conservative protocols and rigorous photoprotection for darker skin phototypes or patients with active pigmentary disease.
If your primary focus is procedural safety: Confirm cardiovascular stability, blood-pressure control, systemic disease stability, and the patient’s ability to follow postoperative care.

Safe ablative resurfacing begins with selecting patients whose skin, systemic health, and aftercare capacity can support predictable wound healing.

Summary Table:

Contraindication	Key Concern	Management Strategy
Recent isotretinoin use	Impaired wound healing, scarring	Wait 6-12 months or per guidelines
Keloid/hypertrophic scar history	Abnormal scarring	Consider nonablative alternatives
Immunosuppression	Delayed healing, infection	Optimize medical status
Collagen vascular disease	Altered wound repair	Specialist assessment
Prior radiation/phenol peel	Damaged adnexal structures	Cautious evaluation
Active infection	Spread, delayed healing	Defer until resolved
Herpes simplex history	Reactivation risk	Prophylactic antivirals
Koebnerizing dermatoses (vitiligo, psoriasis)	New lesions	Defer until stable
Poorly controlled systemic disease (CV, HTN, DM)	Procedural and healing risks	Stabilize before treatment

Ensure safe and effective outcomes for your patients with BELIS's advanced aesthetic devices. Our portfolio includes ablative and non-ablative lasers, IPL, and more, designed for clinics and premium salons. Contact our experts today to discuss your needs and see how our technology can enhance your practice. Get in touch with us to learn more about our products and support.